GSK’s newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech
South Korean biotech ABL Bio has lined up another platform license agreement with a European pharma giant in the area of neurodegenerative diseases. ABL Bio has now garnered the interest of GSK, which will hand ...
